Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial

Abstract Favipiravir is considered a potential treatment for COVID-19 due its efficacy against different viral infections. We aimed to explore the safety and efficacy of favipiravir in treatment of COVID-19 mild and moderate cases. It was randomized-controlled open-label interventional phase 3 clini...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hany M. Dabbous, Manal H. El-Sayed, Gihan El Assal, Hesham Elghazaly, Fatma F. S. Ebeid, Ahmed F. Sherief, Maha Elgaafary, Ehab Fawzy, Sahar M. Hassany, Ahmed R. Riad, Mohamed A. TagelDin
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/2801616f9f1a4ec286b074ac78b065d0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2801616f9f1a4ec286b074ac78b065d0
record_format	dspace
spelling	oai:doaj.org-article:2801616f9f1a4ec286b074ac78b065d02021-12-02T14:25:15ZSafety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial10.1038/s41598-021-85227-02045-2322https://doaj.org/article/2801616f9f1a4ec286b074ac78b065d02021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-85227-0https://doaj.org/toc/2045-2322Abstract Favipiravir is considered a potential treatment for COVID-19 due its efficacy against different viral infections. We aimed to explore the safety and efficacy of favipiravir in treatment of COVID-19 mild and moderate cases. It was randomized-controlled open-label interventional phase 3 clinical trial [NCT04349241]. 100 patients were recruited from 18th April till 18th May. 50 patients received favipiravir 3200 mg at day 1 followed by 600 mg twice (day 2–day 10). 50 patients received hydroxychloroquine 800 mg at day 1 followed by 200 mg twice (day 2–10) and oral oseltamivir 75 mg/12 h/day for 10 days. Patients were enrolled from Ain Shams University Hospital and Assiut University Hospital. Both arms were comparable as regards demographic characteristics and comorbidities. The average onset of SARS-CoV-2 PCR negativity was 8.1 and 8.3 days in HCQ-arm and favipiravir-arm respectively. 55.1% of those on HCQ-arm turned PCR negative at/or before 7th day from diagnosis compared to 48% in favipiravir-arm (p = 0.7). 4 patients in FVP arm developed transient transaminitis on the other hand heartburn and nausea were reported in about 20 patients in HCQ-arm. Only one patient in HCQ-arm died after developing acute myocarditis resulted in acute heart failure. Favipiravir is a safe effective alternative for hydroxychloroquine in mild or moderate COVID-19 infected patients.Hany M. DabbousManal H. El-SayedGihan El AssalHesham ElghazalyFatma F. S. EbeidAhmed F. SheriefMaha ElgaafaryEhab FawzySahar M. HassanyAhmed R. RiadMohamed A. TagelDinNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Hany M. Dabbous Manal H. El-Sayed Gihan El Assal Hesham Elghazaly Fatma F. S. Ebeid Ahmed F. Sherief Maha Elgaafary Ehab Fawzy Sahar M. Hassany Ahmed R. Riad Mohamed A. TagelDin Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial
description	Abstract Favipiravir is considered a potential treatment for COVID-19 due its efficacy against different viral infections. We aimed to explore the safety and efficacy of favipiravir in treatment of COVID-19 mild and moderate cases. It was randomized-controlled open-label interventional phase 3 clinical trial [NCT04349241]. 100 patients were recruited from 18th April till 18th May. 50 patients received favipiravir 3200 mg at day 1 followed by 600 mg twice (day 2–day 10). 50 patients received hydroxychloroquine 800 mg at day 1 followed by 200 mg twice (day 2–10) and oral oseltamivir 75 mg/12 h/day for 10 days. Patients were enrolled from Ain Shams University Hospital and Assiut University Hospital. Both arms were comparable as regards demographic characteristics and comorbidities. The average onset of SARS-CoV-2 PCR negativity was 8.1 and 8.3 days in HCQ-arm and favipiravir-arm respectively. 55.1% of those on HCQ-arm turned PCR negative at/or before 7th day from diagnosis compared to 48% in favipiravir-arm (p = 0.7). 4 patients in FVP arm developed transient transaminitis on the other hand heartburn and nausea were reported in about 20 patients in HCQ-arm. Only one patient in HCQ-arm died after developing acute myocarditis resulted in acute heart failure. Favipiravir is a safe effective alternative for hydroxychloroquine in mild or moderate COVID-19 infected patients.
format	article
author	Hany M. Dabbous Manal H. El-Sayed Gihan El Assal Hesham Elghazaly Fatma F. S. Ebeid Ahmed F. Sherief Maha Elgaafary Ehab Fawzy Sahar M. Hassany Ahmed R. Riad Mohamed A. TagelDin
author_facet	Hany M. Dabbous Manal H. El-Sayed Gihan El Assal Hesham Elghazaly Fatma F. S. Ebeid Ahmed F. Sherief Maha Elgaafary Ehab Fawzy Sahar M. Hassany Ahmed R. Riad Mohamed A. TagelDin
author_sort	Hany M. Dabbous
title	Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial
title_short	Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial
title_full	Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial
title_fullStr	Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial
title_full_unstemmed	Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial
title_sort	safety and efficacy of favipiravir versus hydroxychloroquine in management of covid-19: a randomised controlled trial
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/2801616f9f1a4ec286b074ac78b065d0
work_keys_str_mv	AT hanymdabbous safetyandefficacyoffavipiravirversushydroxychloroquineinmanagementofcovid19arandomisedcontrolledtrial AT manalhelsayed safetyandefficacyoffavipiravirversushydroxychloroquineinmanagementofcovid19arandomisedcontrolledtrial AT gihanelassal safetyandefficacyoffavipiravirversushydroxychloroquineinmanagementofcovid19arandomisedcontrolledtrial AT heshamelghazaly safetyandefficacyoffavipiravirversushydroxychloroquineinmanagementofcovid19arandomisedcontrolledtrial AT fatmafsebeid safetyandefficacyoffavipiravirversushydroxychloroquineinmanagementofcovid19arandomisedcontrolledtrial AT ahmedfsherief safetyandefficacyoffavipiravirversushydroxychloroquineinmanagementofcovid19arandomisedcontrolledtrial AT mahaelgaafary safetyandefficacyoffavipiravirversushydroxychloroquineinmanagementofcovid19arandomisedcontrolledtrial AT ehabfawzy safetyandefficacyoffavipiravirversushydroxychloroquineinmanagementofcovid19arandomisedcontrolledtrial AT saharmhassany safetyandefficacyoffavipiravirversushydroxychloroquineinmanagementofcovid19arandomisedcontrolledtrial AT ahmedrriad safetyandefficacyoffavipiravirversushydroxychloroquineinmanagementofcovid19arandomisedcontrolledtrial AT mohamedatageldin safetyandefficacyoffavipiravirversushydroxychloroquineinmanagementofcovid19arandomisedcontrolledtrial
_version_	1718391416399331328

Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial

Ejemplares similares